Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs

American Journal of Veterinary Research

Volumn 66, Issue 2, 2005, Pages 330-341

  Center, Sharon A ^a   Warner, Karen L ^a   McCabe, Jennifer ^a   Foureman, Polly ^a   Hoffmann, Walter E ^b   Erb, Hollis N ^a  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; GLUCOCORTICOID; GLUTATHIONE; GLYCOGEN; HAPTOGLOBIN; PLACEBO; PREDNISOLONE; S ADENOSYLMETHIONINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; ERYTHROCYTE; FEMALE; LIVER; LIVER DISEASE; LONG TERM CARE; MALE; NONHUMAN; PILOT STUDY; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 14844334921     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.330     Document Type: Article

References (89)

1. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine: a review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
2. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 1987;83:35-42.
3. Mudd SH, Poole JR. Labile methyl group balances for normal humans in various dietary regimens. Metabolism 1975;24:721-735.
4. Mato JM, Corrales F, Martin-Duce A, et al. Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: part 1. Drugs 1990;40:58-64.
5. Almasio P, Bortolini M, Pagliaro L, et al. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-123.
6. Bottigheri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76(suppl)1151-1157.
7. Chawla RK, Bonkovsky HL, Galambo JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 1990;40:98-110.
8. Mato JM, Corrales FJ, Lu SC, et al. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 2002;16:15-26.
9. Arrigo A-P. Gene expression and the thiol redox state. Free Radic Biol Med 1999;27:936-944.
10. Finkelstein JD, Kyle WE, Martin JJ, et al. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 1975;66:81-87.
11. Center SA. Chronic liver disease: current concepts of disease mechanisms. J Small Anim Pract 1999;40:106-114.
12. Bomzon A, Ljubuncic P. Oxidative stress and vascular smooth muscle cell function in liver disease. Pharmacol Ther 2001;89:295-308.
13. Poli G. Liver damage due to free radicals. Br Med Bull 1993;49:604-620.
14. Paradis V, Kollinger M, Fabre M, et al. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997;26:135-142.
15. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002;22:137-144.
16. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. Am J Vet Res 2002;63:1187-1197.
17. Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestasis patients with liver disease. Drug Invest 1992;4(suppl 4E):90-100.
18. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407-415.
19. Martinez-Chantar ME, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002;76:1177S-1182S.
20. Arias-Diaz J, Vara E, Garcia C, et al. S-adenosylmethionine protects hepatocytes; against the effects of cytokines. J Surg Res 1996;62:79-84.
21. Micali M, Chiti D, Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver disease. Curr Ther Res 1983;33:1004-1013.
22. Leiber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76(suppl):1183S-1187S.
23. Frezza M, Terpin M. The use of S-adenosyl-L-methionine in the treatment of cholestatic disorders. A meta-analysis of clinical trials. Drug Invest 1992;4:101-108.
24. Center SA. Hepatic lipidosis, glucocorticoid hepatopathy, vacuolar hepatopathy, storage disorders, amyloidosis, and iron toxicity. In: Guilford WG, Center SA, Strombeck DR, et al, eds. Strombeck's small animal gastroenterology. 3rd ed. Philadelphia: WB Saunders Co, 1996;766-801.
25. Badylak SF, Van Vleet JF. Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy. Am J Vet Res 1981;42:1310-1318.
26. Badylak SF, Van Vleet JF. Tissue γ-glutamyl transpeptidase activity and hepatic ultrastructural alterations in dogs with experimentally induced glucocorticoid hepatopathy. Am J Vet Res 1982;43:649-655.
27. Fittschen C, Bellamy JE. Prednisone-induced morphologic and chemical changes in the liver of dogs. Vet Pathol 1984; 21:399-401.
28. Thompson SW, Sparano BM, Diener RM. Vacuoles in the hepatocytes of cortisone treated dogs. Am J Pathol 1971; 63:125-141.
29. Rutgers HC, Batt RM, Vaillant C, et al. Subcellular pathologic features of glucocorticoid-induced hepatopathy in dogs. Am J Vet Res 1995;56:898-908.
30. Denovo RC, Prasse KW. Comparison of serum biochemical and hepatic functional alterations in dogs treated with corticesteroids and hepatic duct ligation. Am J Vet Res 1983;44:1703-1709.
31. Moore GE, Mahaffey EA, Hoenig M. Hematologic and serum biochemical effects of long-term administration of anti-inflammatory doses of prednisone in dogs. Am J Vet Res 1992;53:1033-1037.
32. Dillon AR, Sorjonen DC, Powers RD, et al. Effects of dexamethasone and surgical hypotension on hepatic morphologic features and enzymes of dogs. Am J Vet Res 1983;44:1996-2000.
33. Solter PF, Hoffmann WE, Chambers MD, et al. Hepatic total 3α-hydroxy bile acids concentration and enzyme activities in prednisone-treated dogs. Am J Vet Res 1994;55:1086-1092.
34. Wiedmeyer CE, Solter PF. Validation of human haptoglobin immunoturbimetric assay for detection of haptoglobin in equine and canine serum and plasma. Vet Clin Pathol 1996;25:141-146.
35. Hoffmann WE, Sanecki RK, Dorner JL. A technique for automated quantification of canine glucocorticoid-induced isoenzyme of alkaline phosphatase. Vet Clin Pathol 1991;17:66-70.
36. Center SA, Leveille CR, Baldwin BH, et al. Direct spectrometric determination of serum bile acids in the dog and cat. Am J Vet Res 1984;45:2043-2050.
37. Bonasch H, Cornelius CE. Indocyanine green clearance - a liver function test for the dog. Am J Vet Res 1964;25:254-256.
38. Prins HK, Loos JA. Glutathione. In: Yunis J, ed. Biochemical methods in red cell genetics. New York: Academic Press Inc, 1969;115-137.
39. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61:882-888.
40. Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
41. Kwon TW, Watts BM. Determination of malonaldehyde by ultraviolet spectrophotometry. J Food Sci 1963;28:627-630.
42. Wise CK, Cooney CA, Ali SF, et al. Measuring S-adenosyl-methionine in whole blood, red blood cells and cultured cells using a fast preparation method and high-performance liquid chromatography. J Chromatogr 1997;696:145-152.
43. Leiber CS, Casini A, DeCarli LM, et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990;11:165-172.
44. Hirata H, Kasama T, Sawai Y, et al. Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and predinsone in human serum by reversed-phase high-performance liquid chromatography. J Chromatog Biomed Appl 1994;658:55-61.
45. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207-212.
46. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86:271-278.
47. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
48. Downs TR, Wilfinger WW. Fluorometric quantification of DNA in cells and tissue. Anal Biochem 1983;131:538-547.
49. Seetharam S, Sussman NL, Komoda T, et al. The mechanisms of elevated alkaline phosphatase activity after bile duct ligation in the rat. Hepatology 1986;6:374-380.
50. Hatoff DE, Hardison WG. Bile acids modify alkaline phosphatase induction and bile secretion pressure after bile duct obstruction in the rat. Gastroenterology 1981;80:666-672.
51. Schlaeger R, Haux P, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. Enzyme 1982;28:3-13.
52. Ogawa H, Mink J, Hardison WG, et al. Alkaline phosphatase activity in hepatic tissue and serum correlates with amount and type of bile acid load. Lab Invest 1990;62:87-95.
53. Solter PF, Hoffmann WE. Solubilization of liver alkaline phosphatase isoenzyme during cholestasis in dogs. Am J Vet Res 1999;60:1010-1015.
54. Solter PF, Hoffmann WE. Canine corticosteroid-induced alkaline phosphatase in serum was solubilized by phospholipase activity in vivo. Am J Physiol 1995;269: G278-G286.
55. Harvey JW, West CL. Prednisone-induced increases in serum alpha-2-globulin and haptoglobin concentrations in dogs. Vet Pathol 1987;24:90-92.
56. Solter PF, Hoffmann WE, Hungerford LL, et al. Haptoglobin and ceruloplasmin as determinants of inflammation in dogs. Am J Vet Res 1991;52:1738-1742.
57. Flusser G, Ginzburg V, Meyuhas O. Glucocorticoids induce transcription of ribosomal protein genes in rat liver. Mol Cell Endocrinol 1989;64:213-222.
58. Grombacher T, Mitra S, Kaina B. Induction of the alkyl-transferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996;17:2329-2336.
59. Tsiriyotis C, Spandidos DA, Sekeris CE. The mitochondrion as a primary site of action of glucocorticoids: mitochondrial nucleotide sequences, showing similarity to hormone response elements, confer dexamethasone inducibility to chimaeric genes transfected in LATK-cells. Biochem Biophys Res Commun 1997;18:349-354.
60. Muriel P, Mourelle M. Characterization of membrane fraction lipid composition and function of cirrhotic rat liver. Role of S-adenosyl-L-methionine. J Hepatol 1992;14:16-21.
61. Muriel P, Suarez OR, Gonzalez MP, et al. Effect of S-adenosyl-L-methionine on liver damage induced by biliary obstruction. J Hepatol 1994;21:95-102.
62. Deleve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 1991;52:287-305.
63. Jungermann K, Katz N. Functional hepatocellular heterogeneity. Hepatology 1982;2:385-395.
64. Beutler E. Energy metabolism and maintenance of erythrocytes. In: Williams WJ, Beutler E, Erslev A, et al, eds. Hematology. 4th ed. New York: McGraw-Hill Book Co, 1990;355-368.
65. Dass PD, Bermes EW Holmes EW. Renal and hepatic output of glutathione in plasma and whole blood. Biochem Biophys Acta 1992;1156:99-102.
66. Clemens MR, Waller HD. Lipid peroxidation in erythrocytes. Chem Phys Lipids 1987;45:251-268.
67. Kaneko JJ. Comparative erythrocyte metabolism. In: Brandly CA, Cornelius CE, eds. Advances in veterinary science and comparative medicine. New York: Academic Press Inc, 1974;117-153.
68. Harvey JW, Kaneko JJ. Erythrocyte enzyme activities and glutathione levels of the horse, cat, dog and man. Comp Biochem Physiol 1975;52B:507-510.
69. Kurata M, Suzuki M, Agar NS. Antioxidant systems and erythrocyte life-span in mammals. Comp Biochem Physiol 1993; 106B:477-487.
70. Smith JE, Agar NS. The effect of phlebotomy on canine erythrocyte metabolism. Res Vet Sci 1975;18:231-236.
71. Rettig MP, Low PS, Gimm A, et al. Evaluation of biochemical changes during in vivo erythrocyte senescence in the dog. Blood 1999;93:376-384.
72. Vajdovich P, Gaal T, Szilagyi A, et al. Changes in some red blood cell and clinical laboratory parameters in young and old beagle dogs. Vet Res Commun 1997;21:463-470.
73. Pennings HJ, Borm PJ, Evelo CT, et al. Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate. Eur Respir J 1999; 13:1260-1266.
74. Orzechowski A, Ostaszewski P, Wilczak J, et al. Rats with a glucocorticoid-induced catabolic state show symptoms of oxidative stress and spleen atrophy: the effects of age and recovery. J Vet Med 2002;49:256-263.
75. Suzuki H, Sugiyama Y. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 1998;18:359-376.
76. Keppler D, Leier I, Jedlitschky G, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact 1998;111-112:153-161.
77. Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003;17:103-114.
78. Falkner KC, Pinaire JA, Xiao G-H, et al. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2001;60:611-619.
79. Courtois A, Payen L, Guillouzo A, et al. Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett 1999;459:381-385.
80. Lu SC, Ge JL, Kuhlenkamp J, et al. Insulin and glucocorticoid dependence of hepatic gamma-glutamylcysteine synthetase and glutathione synthesis in the rat. Studies in cultured hepatocytes and in vivo. J Clin Invest 1992;90:524-532.
81. Tongiani R, Paolicchi A, Nohammer G. Changes in protein sulfur groups in hepatocytes of newborn rats under glucocorticoid stimulation. Basic Appl Histochem 1987;31:441-445.
82. Cai J, Huang ZZ, Lu SC. Differential regulation of gamma-glutamylcysteine synthetase heavy and light subunit gene expression. Biochem J 1997;326:167-172.
83. Boza JJ, Turini M, Moennoz D, et al. Effect of glutamine supplementation of the diet on tissue protein synthesis rate of glucocorticoid-treated rats. Nutrition 2001;17:35-40.
84. McIntosh LJ, Hong KE, Sapolsky RM. Glucocorticoids may alter antioxidant enzyme capacity in the brain: baseline studies. Brain Res 1998;791:209-214.
85. Kawamura T, Yoshioka T, Bills T, et al. Glucorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries. Kidney Int 1991;40:291-301.
86. Beatriz G, Pajares MA, Mato JM, et al. Glucocorticoid regulation of hepatic S-Adenosylmethionine synthetase gene expression. Endocrinology 1997;138:1251-1258.
87. Ziesel SM, Poole JR. Dietary intake of methionine: influence on brain S-adenosylmethionine. In: Usdin E, Borchardt RT, Creveling CR, eds. Transmethylations. Amsterdam, The Netherlands: Elsevier/North-Holland, 1979;59-68.
88. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol 2000;15:718-724.
89. Townsend DM, Tew K, Tapier H. The importance of glutathione in human disease. Biomed Pharmacother 2003;57:145-155.